Author

Carla P. Martins

AstraZeneca (United Kingdom)ORCID 0000-0002-8288-1686Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A.R. Phillips· 1 shared Abdel Wahad Bidar· 1 shared Alice T. Browne· 1 shared Alyson SpeediD· 1 shared Amir Taheri‐GhahfarokhiiD· 1 shared Anders LundiniD· 1 shared Anna Schantz· 1 shared Babak Alaei-MahabadiiD· 1 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A.R. Phillips

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mutant KRAS dosage contributes to heterogeneity in lung cancer therapeutic response

Alice T. Browne, Chris McCann, William J. McDaid, Nikita Lewis, Sandhya Sridhar, Gary Joseph Doherty, Deborah Y. Moss, Matilda Downs, Stephen Marry, A.R. Phillips, Connor N. Brown, Alyson Speed, Gemma E. Logan, Gera L. Jellema, James R. Bradford, , Emma M. Kerr

This study shows that mutant KRAS dosage affects therapeutic response in lung cancer, with higher dosages linked to resistance to platinum therapy and sensitivity to pS6K inhibition.

bioRxiv · May 9, 2026 · PreprintCancer Biology

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal, Frank Seeliger, Camilla Johansson, Abdel Wahad Bidar, Lukas Badertscher, Emma Jane Davies, Elizabeth L. Hardaker, Carla P. Martins, Therése Admyre, Amir Taheri‐Ghahfarokhi, Jenna Bradley, Anna Schantz, Babak Alaei-Mahabadi, , Marcello Maresca

This paper introduces an inducible CRISPR-Cas9 system for preclinical drug discovery, enabling controlled genome editing in mice to model cancer and test therapies.

bioRxiv · Apr 6, 2020 · PreprintGenomics